These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15818309)

  • 21. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    Walmsley S; Henry K; Katlama C; Nelson M; Castagna A; Reynes J; Clotet B; Hui J; Salgo M; DeMasi R; Delehanty J
    J Infect Dis; 2003 Dec; 188(12):1827-33. PubMed ID: 14673761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reassessment of enfuvirtide's role in the management of HIV-1 infection.
    Marr P; Walmsley S
    Expert Opin Pharmacother; 2008 Sep; 9(13):2349-62. PubMed ID: 18710359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
    AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
    Trottier B; Walmsley S; Reynes J; Piliero P; O'Hearn M; Nelson M; Montaner J; Lazzarin A; Lalezari J; Katlama C; Henry K; Cooper D; Clotet B; Arastéh K; Delfraissy JF; Stellbrink HJ; Lange J; Kuritzkes D; Eron JJ; Cohen C; Kinchelow T; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Bourdeau L; Natale C; Hughes F; Chung J; Guimaraes D; Drobnes C; Bader-Weder S; Demasi R; Smiley L; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):413-21. PubMed ID: 16280695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
    Clotet B; Raffi F; Cooper D; Delfraissy JF; Lazzarin A; Moyle G; Rockstroh J; Soriano V; Schapiro J
    AIDS; 2004 May; 18(8):1137-46. PubMed ID: 15166529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Enfuvirtide: the first step for a new strategy of antiretroviral therapy].
    Bottaro EG
    Medicina (B Aires); 2007; 67(2):195-205. PubMed ID: 17593608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction.
    Shahar E; Moar C; Pollack S
    AIDS; 2005 Mar; 19(4):451-2. PubMed ID: 15750403
    [No Abstract]   [Full Text] [Related]  

  • 32. New partnership calls for clinical testing of two fusion inhibitors.
    Slovick J
    Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
    [No Abstract]   [Full Text] [Related]  

  • 33. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 34. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC; McNicholl IR
    Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enfuvirtide approved for defusing HIV.
    Burton A
    Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
    [No Abstract]   [Full Text] [Related]  

  • 38. Enfuvirtide.
    Dando TM; Perry CM
    Drugs; 2003; 63(24):2755-66; discussion 2767-8. PubMed ID: 14664654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 40. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.